Abstract 1965P
Background
Chordomas are rare neoplasms of notochord origin that can affect the skull base and mobile spine. While surgery and radiation are effective means to treat localized disease, there are no standard systemic therapies to treat locally advanced/metastatic chordomas. We previously published a series of chordoma patients treated with immune checkpoint inhibitors demonstrating limited activity. Here we begin to evaluate the immune microenvironment of chordomas by transcriptional analysis.
Methods
57 tissue samples (30 spine chordoma, 21 skull base chordoma, 6 normal), previously analyzed by RNA-sequencing analysis and published (PMID: 28844110), were used. Hierarchical clustering was used to evaluate expression of immune-related genes. Gene ontology analysis was performed with GeneAnalytics. Microenvironment Cell Populations-counter (MCP-counter) was used for quantification of immune cell populations. Spearman’s rank correlation coefficient and t-tests were used for statistical purposes.
Results
Populations of endothelial cells were significantly different in skull base (SB) samples (p<0.05) and mobile spine (MS) samples (p<0.01) compared to normal. B cells were significantly different in MS compared to normal (p<0.05), and monocytes were significantly different in SB samples compared to normal (p<0.001). 19 genes of the Interferon gamma (IFNG) gene pathway were significantly altered (p<0.05) in SB samples compared to MS samples but only 4 genes of the IFNG pathway were significantly altered (p<0.05) in SB samples compared to normal samples. 9 genes of the IFNG pathway were significantly altered in MS samples compared to normal (p<0.05). Hierarchical clustering of immune-related gene expression revealed 3 distinct groups. Gene ontology analysis revealed that group 1 favored NF-kappa B signaling pathway, group 2 favored the phagosome pathway, and group 3 represented dendritic cell development lineage pathway.
Conclusions
Chordomas of the skull base and mobile spine exhibit diverse immune cell populations and differential expression of mediators of immune response. A comprehensive analysis is needed to further our understanding of the immune microenvironment of chordoma to develop ideal immunotherapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A.P. Conley: Other, Institutional, Research Funding, clinical trial support: Chordoma Foundation, Epicentrx; Other, Personal and Institutional, Research Funding, clinical trial support; consulting: Inhibrx; Financial Interests, Personal, Advisory Board, consulting: Aadi Biosciences. All other authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15